BiotechTube
Sidewinder Therapeutics

Sidewinder Therapeutics

San Diego, United States· Est.
sidewinderbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Sidewinder Therapeutics is an early-stage, private biotech developing next-generation precision biologics, primarily bispecific antibody-drug conjugates (ADCs), for oncology and rare diseases. The company is built by a team of serial entrepreneurs and experienced drug developers and has secured a strategic partnership with Lonza's Synaffix for its ADC linker-payload technology. While still in the pre-clinical stage, Sidewinder is positioning itself in the competitive but high-growth ADC therapeutics space with a focus on novel targeting and payload delivery.

OncologyRare Diseases

Technology Platform

Focus on next-generation, precision bispecific Antibody-Drug Conjugates (ADCs). Utilizes licensed technology from Lonza's Synaffix (GlycoConnect, HydraSpace, toxSYN) for optimized antibody conjugation, linker-payload stability, and potency.

Funding History

1
Total raised:$12M
Seed$12M

Opportunities

The ADC market is experiencing rapid growth and innovation.
Sidewinder's focus on bispecific ADCs and rare diseases positions it in high-value, differentiated niches within this expanding field.
The partnership with Synaffix provides validated technology and de-risks early platform development.

Risk Factors

High scientific risk as an early-stage company with undisclosed, novel targets and an unproven bispecific ADC platform.
Faces intense competition in the ADC space from large pharma and well-funded biotechs.
Reliant on future fundraising to advance programs to the clinic.

Competitive Landscape

Sidewinder operates in the highly competitive ADC therapeutics landscape, competing with giants like AstraZeneca/Daiichi Sankyo, Pfizer, and Gilead, as well as numerous ADC-focused biotechs (e.g., ImmunoGen, ADC Therapeutics, Mersana). Its differentiation hinges on the novel application of bispecific antibodies for targeted payload delivery.

More companies in Biologics / Biosimilars →More companies in United States →